イスラエル -
ヘブライ語 -
Ministry of Health
פרבסטאטין טבע 40 מג
teva pharmaceutical industries ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 40 mg - hmg coa reductase inhibitors - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa
イスラエル -
ヘブライ語 -
Ministry of Health
פרבסטאטין טבע 40 מג
teva israel ltd - pravastatin sodium - טבליה - pravastatin sodium 40 mg - hmg coa reductase inhibitors - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa
イスラエル -
ヘブライ語 -
Ministry of Health
פרילידן
halperin n.h. medic ltd, israel - lidocaine; prilocaine - קרם - prilocaine 25 mg / 1 g; lidocaine 25 mg / 1 g - prilocaine
イスラエル -
ヘブライ語 -
Ministry of Health
אוקספה
abbott medical laboratories ltd - acid casein 5.9 g / 100 ml; artificial vanilla 116 mg / 100 ml - liquid - combinations of electrolytes - oxepa is clinically shown to modulate the inflammatory response in critically ill, mechanically ventilated patients. it is appropriate for patients who have sepsis, ali (acute lung injury), or ards (acute respiratory distress syndrome).
イスラエル -
ヘブライ語 -
Ministry of Health
מולטאק
sanofi israel ltd - dronedarone - טבליות מצופות פילם - dronedarone 400 mg - dronedarone - dronedarone - multaq is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (af). due to its safety profile, multaq should only be prescribed after alternative treatment options have been considered.multaq should not be given to patients with left ventricular systolic dysfunction or to patients with current or previous episodes of heart failure.
イスラエル -
ヘブライ語 -
Ministry of Health
אסריל 25
dexcel ltd, israel - captopril - טבליה - captopril 25 mg - captopril - captopril - hypertension, congestive heart failure, insulin dependent diabetic nephropathy in hypertensive and non hypertensive patients in cases where the serum creatinine level < 2.5 mg/dl. left ventricular dysfunction after myocardial infarction. captopril is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction < or equals to 40 % and to reduce the incidence of overt heart failure and subsequent hospitalization for congestive heart failure in these patients.
イスラエル -
ヘブライ語 -
Ministry of Health
אסריל 50
dexcel ltd, israel - captopril - טבליה - captopril 50 mg - captopril - captopril - hypertension, congestive heart failure, insulin dependent diabetic nephropathy in hypertensive and non hypertensive patients in cases where the serum creatinine level < 2.5 mg/dl. left ventricular dysfunction after myocardial infarction. captopril is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction < or equals to 40 % and to reduce the incidence of overt heart failure and subsequent hospitalization for congestive heart failure in these patients.
イスラエル -
ヘブライ語 -
Ministry of Health
דיובאן 80 מג טבליות מצופות
novartis israel ltd - valsartan - טבליות מצופות פילם - valsartan 80 mg - valsartan - valsartan - for treatment of hypertension. diovan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial diovan signicantly reduced hospitalisations for heart failure. there is no evidence that diovan provides added benefits when it is used with an adequate dose of an ace inhibitor. diovan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.